Biocardia and cellprothera enhance collaboration for development of protheracytes™ for the treatment of acute myocardial infarction in europe and potential early access for patients

Sunnyvale, calif. and mulhouse, france, feb. 01, 2023 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and cellprothera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their clinical research supply and support agreement.
BCDA Ratings Summary
BCDA Quant Ranking